国产人工心脏龙头，三年半烧掉10.6亿

Core Viewpoint - The artificial heart, known as the "crown jewel" of medical devices, is entering a period of accelerated capitalization, with Suzhou Tongxin Medical Technology Co., Ltd. aiming to become the first domestic company to go public in this sector [1]. Company Overview - Tongxin Medical's core product, CH-VAD, is the first fully magnetic levitation implantable artificial heart approved for sale in China. However, the company has struggled with profitability since its commercialization began four years ago, facing intense competition from other companies [2][3]. Financial Performance - The company is experiencing a typical "high R&D, high growth, high loss" dilemma, with revenues from 2022 to mid-2025 projected at approximately 8.61 million, 50.45 million, 77.35 million, and 72.07 million yuan, respectively. Net losses during the same period are expected to exceed 1.06 billion yuan [4][10]. - R&D expenses are significant, with projections of 93.82 million, 108 million, 148 million, and 93.15 million yuan from 2022 to mid-2025, contributing to ongoing financial losses [6][10]. Market Position and Competition - The company relies heavily on the CH-VAD product, which accounted for 96.9% of its revenue in the first half of 2025. The product's market share has declined to 26.9% by the end of 2024 due to increased competition and price reductions [11][13]. - The company has reduced the price of CH-VAD from 459,600 yuan in 2022 to 362,300 yuan in the first half of 2025, a decrease of 26.8%, in an attempt to maintain market share [13]. Sales and Customer Concentration - The company has a high customer concentration, with the top five customers accounting for 86.73% of sales in 2024. The largest customer, Quankeda, represented over 50% of sales in 2023 [16][18]. International Expansion - The company is focusing on international markets, with its BrioVAD product being the first Chinese active implantable medical device to enter clinical trials in the U.S. This product is expected to generate significant revenue, contributing 29.61 million yuan in the first half of 2025 [18][19]. - The company plans to raise 1.064 billion yuan through its IPO, with a significant portion allocated to global clinical trials and registration for BrioVAD, indicating a strong commitment to international expansion [19].